Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer Health Study Area: Breast Cancer For Caregivers For Caregivers For Clinicians Communities FAQs For Parents For Parents For Patients For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH Instagram Created with sketchtool. For Clinicians

Please Log In/Join Now first, and then use this function!

Not Yet Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications - IM103-402

Updated: 6 May, 2021   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 3

    Phase

  • Gender(s)

  • 12-17

    Age Range

  • 12

    Location(s)

  • Not Yet Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap
Drug: Mycophenolate Mofetil Drug: Cyclosporine A Drug: Corticosteroids Drug: Tacrolimus Drug: Enteric Coated Mycophenolate Sodium Biological: Belatacept
Active Comparator: Arm 2: Continue calcineurin inhibitor-based regimen
Drug: Tacrolimus Drug: Cyclosporine A Drug: Corticosteroids Drug: Enteric Coated Mycophenolate Sodium Drug: Mycophenolate Mofetil

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Male and female adolescents 12 to less than 18 years of age - Recipients of a renal allograft from a living or deceased donor transplanted at least 6 calendar months prior to enrollment - Receiving a stable regimen of a calcineurin inhibitor (CNI), with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium/mycophenolate mofetil (EC-MPS/MPA), with or without daily corticosteroids for ≥1 calendar months prior to randomization - Clinically stable renal function during the 12-week period prior to screening, in the opinion of the investigator and based on protocol-defined criteria for proteinuria and estimated glomerular filtration rate (eGFR) - Serologic evidence of past exposure to Epstein-Barr virus (EBV) and current absence of EBV DNA replication at or prior to renal transplantation and during the Screening period Exclusion Criteria: - Recipients with EBV serostatus negative or unknown at screening or at transplant - Treatment for biopsy-proven acute rejection (BPAR) of any degree of severity within 6 calendar months prior to enrollment - Biopsy-confirmed antibody-mediated acute rejection at any time with the current allograft - Banff 97 grade IIA or higher acute cellular rejection (or equivalent), or treatment with plasmapheresis or rituximab for any acute rejection at any time with the current allograft - Current evidence or past history of active or inadequately treated latent tuberculosis (TB) infection - Previously treated with belatacept or previously enrolled in a belatacept trial with their present allograft Other inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com